64.56 USD
-0.44 (-0.68%)
65 USD
+0.44 (+0.68%)
We assign a fundamental rating of 4 out of 10 to ARWR. ARWR was compared to 528 industry peers in the Biotechnology industry. ARWR has an average financial health and profitability rating. ARWR is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year ARWR has reported negative net income.
In the past year ARWR had a positive cash flow from operations.
In the past 5 years ARWR always reported negative net income.
The reported operating cash flow has been mixed in the past 5 years: ARWR reported negative operating cash flow in multiple years.
1.2 Ratios
ARWR has a Return On Assets of -0.12%. This is amongst the best in the industry. ARWR outperforms 88.30% of its industry peers.
With an excellent Return On Equity value of -0.35%, ARWR belongs to the best of the industry, outperforming 89.81% of the companies in the same industry.
ARWR's Return On Invested Capital of 4.83% is amongst the best of the industry. ARWR outperforms 91.51% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.12% | ||
| ROE | -0.35% | ||
| ROIC | 4.83% |
ROA(3y)-26.51%
ROA(5y)-24.96%
ROE(3y)-133.1%
ROE(5y)-95.59%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ARWR's Operating Margin of 11.86% is amongst the best of the industry. ARWR outperforms 92.08% of its industry peers.
ARWR does not have Profit Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 11.86% | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so ARWR is destroying value.
Compared to 1 year ago, ARWR has more shares outstanding
The number of shares outstanding for ARWR has been increased compared to 5 years ago.
Compared to 1 year ago, ARWR has an improved debt to assets ratio.
2.2 Solvency
ARWR has an Altman-Z score of 5.57. This indicates that ARWR is financially healthy and has little risk of bankruptcy at the moment.
ARWR's Altman-Z score of 5.57 is fine compared to the rest of the industry. ARWR outperforms 73.96% of its industry peers.
The Debt to FCF ratio of ARWR is 3.97, which is a good value as it means it would take ARWR, 3.97 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 3.97, ARWR belongs to the top of the industry, outperforming 92.45% of the companies in the same industry.
A Debt/Equity ratio of 1.25 is on the high side and indicates that ARWR has dependencies on debt financing.
The Debt to Equity ratio of ARWR (1.25) is worse than 75.85% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.25 | ||
| Debt/FCF | 3.97 | ||
| Altman-Z | 5.57 |
ROIC/WACC0.59
WACC8.19%
2.3 Liquidity
ARWR has a Current Ratio of 4.86. This indicates that ARWR is financially healthy and has no problem in meeting its short term obligations.
ARWR has a Current ratio (4.86) which is comparable to the rest of the industry.
A Quick Ratio of 4.86 indicates that ARWR has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 4.86, ARWR is in line with its industry, outperforming 56.98% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.86 | ||
| Quick Ratio | 4.86 |
3. Growth
3.1 Past
ARWR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 98.40%, which is quite impressive.
Looking at the last year, ARWR shows a very strong growth in Revenue. The Revenue has grown by 23258.15%.
ARWR shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 56.63% yearly.
EPS 1Y (TTM)98.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%86.86%
Revenue 1Y (TTM)23258.15%
Revenue growth 3Y50.53%
Revenue growth 5Y56.63%
Sales Q2Q%N/A
3.2 Future
ARWR is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 114.38% yearly.
Based on estimates for the next years, ARWR will show a quite strong growth in Revenue. The Revenue will grow by 14.62% on average per year.
EPS Next Y-4018.25%
EPS Next 2Y-648.16%
EPS Next 3Y-233.78%
EPS Next 5Y114.38%
Revenue Next Year-45.38%
Revenue Next 2Y-39.16%
Revenue Next 3Y-10.46%
Revenue Next 5Y14.62%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
ARWR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ARWR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, ARWR is valued cheaply inside the industry as 90.38% of the companies are valued more expensively.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of ARWR indicates a rather cheap valuation: ARWR is cheaper than 92.64% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 55.89 | ||
| EV/EBITDA | 63.63 |
4.3 Compensation for Growth
A cheap valuation may be justified as ARWR's earnings are expected to decrease with -233.78% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-648.16%
EPS Next 3Y-233.78%
5. Dividend
5.1 Amount
No dividends for ARWR!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
64.56
-0.44 (-0.68%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners84.75%
Inst Owner Change0.24%
Ins Owners3.83%
Ins Owner Change-0.65%
Market Cap8.77B
Revenue(TTM)829.45M
Net Income(TTM)-1.63M
Analysts79
Price Target63.08 (-2.29%)
Short Float %7.89%
Short Ratio4.18
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)3.1%
Min EPS beat(2)-20.51%
Max EPS beat(2)26.7%
EPS beat(4)2
Avg EPS beat(4)314.12%
Min EPS beat(4)-211.36%
Max EPS beat(4)1461.66%
EPS beat(8)2
Avg EPS beat(8)64.89%
EPS beat(12)3
Avg EPS beat(12)32.54%
EPS beat(16)4
Avg EPS beat(16)33.96%
Revenue beat(2)2
Avg Revenue beat(2)28.89%
Min Revenue beat(2)14.81%
Max Revenue beat(2)42.98%
Revenue beat(4)3
Avg Revenue beat(4)410.31%
Min Revenue beat(4)-96.63%
Max Revenue beat(4)1680.09%
Revenue beat(8)3
Avg Revenue beat(8)156.63%
Revenue beat(12)4
Avg Revenue beat(12)105.73%
Revenue beat(16)5
Avg Revenue beat(16)73.56%
PT rev (1m)6.49%
PT rev (3m)32.89%
EPS NQ rev (1m)-33.37%
EPS NQ rev (3m)-23.61%
EPS NY rev (1m)-0.21%
EPS NY rev (3m)-17.78%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-6.41%
Revenue NY rev (1m)6.85%
Revenue NY rev (3m)3.29%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 10.57 | ||
| P/FCF | 55.89 | ||
| P/OCF | 48.83 | ||
| P/B | 18.81 | ||
| P/tB | 19.09 | ||
| EV/EBITDA | 63.63 |
EPS(TTM)-0.08
EYN/A
EPS(NY)-3.29
Fwd EYN/A
FCF(TTM)1.16
FCFY1.79%
OCF(TTM)1.32
OCFY2.05%
SpS6.11
BVpS3.43
TBVpS3.38
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.12% | ||
| ROE | -0.35% | ||
| ROCE | 8.27% | ||
| ROIC | 4.83% | ||
| ROICexc | 21.1% | ||
| ROICexgc | 21.65% | ||
| OM | 11.86% | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | 18.91% |
ROA(3y)-26.51%
ROA(5y)-24.96%
ROE(3y)-133.1%
ROE(5y)-95.59%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.6
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.25 | ||
| Debt/FCF | 3.97 | ||
| Debt/EBITDA | 4.76 | ||
| Cap/Depr | 94.73% | ||
| Cap/Sales | 2.73% | ||
| Interest Coverage | 5176.11 | ||
| Cash Conversion | 146.84% | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.86 | ||
| Quick Ratio | 4.86 | ||
| Altman-Z | 5.57 |
F-Score6
WACC8.19%
ROIC/WACC0.59
Cap/Depr(3y)756.37%
Cap/Depr(5y)612.23%
Cap/Sales(3y)1353.35%
Cap/Sales(5y)819.77%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)98.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%86.86%
EPS Next Y-4018.25%
EPS Next 2Y-648.16%
EPS Next 3Y-233.78%
EPS Next 5Y114.38%
Revenue 1Y (TTM)23258.15%
Revenue growth 3Y50.53%
Revenue growth 5Y56.63%
Sales Q2Q%N/A
Revenue Next Year-45.38%
Revenue Next 2Y-39.16%
Revenue Next 3Y-10.46%
Revenue Next 5Y14.62%
EBIT growth 1Y116.37%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-453.64%
EBIT Next 3Y-114.74%
EBIT Next 5Y45.74%
FCF growth 1Y125.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y138.79%
OCF growth 3YN/A
OCF growth 5YN/A
ARROWHEAD PHARMACEUTICALS IN / ARWR FAQ
What is the fundamental rating for ARWR stock?
ChartMill assigns a fundamental rating of 4 / 10 to ARWR.
What is the valuation status of ARROWHEAD PHARMACEUTICALS IN (ARWR) stock?
ChartMill assigns a valuation rating of 2 / 10 to ARROWHEAD PHARMACEUTICALS IN (ARWR). This can be considered as Overvalued.
What is the profitability of ARWR stock?
ARROWHEAD PHARMACEUTICALS IN (ARWR) has a profitability rating of 4 / 10.
How financially healthy is ARROWHEAD PHARMACEUTICALS IN?
The financial health rating of ARROWHEAD PHARMACEUTICALS IN (ARWR) is 6 / 10.
Can you provide the expected EPS growth for ARWR stock?
The Earnings per Share (EPS) of ARROWHEAD PHARMACEUTICALS IN (ARWR) is expected to decline by -4018.25% in the next year.